RNS Number:9552S
Profile Therapeutics PLC
08 December 2003

Immediate Release                                        07:00am 8 December 2003

                            Profile Therapeutics plc

            Profile Agrees To Supply Prodose System To CoTherix Inc.

Profile Therapeutics plc ("Profile"), which develops and commercialises
specialist inhaled therapies, is delighted to announce that US biopharmaceutical
company, CoTherix Inc. have selected Profile's Prodose AAD(R) system as the
delivery platform for their clinical trials of a medicine for Primary Pulmonary
Hypertension ("PPH") in the USA.

Under the terms of the agreement, Profile will supply CoTherix with over 300
Prodose systems for use in the clinical trial programme to bring their Iloprost
nebulising solution, licensed from Schering AG, to the US market.  This order is
worth approximately $1 million (#575,000) to Profile. Schering already have
approval for inhaled Iloprost in Europe as Ventavis(R), and Profile's
proprietary Adaptive Aerosol Delivery ("AAD") systems are indicated for its
delivery.

Primary Pulmonary Hypertension is a rare lung disorder in which the blood
pressure in the pulmonary artery rises far above normal levels for no apparent
reason and may become life-threatening1.  There are approximately 3,000 patients
in the US.

Commenting on today's announcement, John Lisle, CEO of Profile, said:

"We are very pleased to have secured this significant contract which is a
further endorsement of the use of our AAD technology in drug development.  It is
also an important step in developing our business in the US.  We believe it will
be great news for patients as it will give them a state-of-the-art delivery
system to help improve their treatment and quality of life."


                                    - ENDS -


1 Primary Pulmonary Hypertension: division of lung diseases and office of
prevention, education and control.  US department of Health and Human Services.
Public Health Service. National Institutes of Health.  National Heart, Lung and
Blood Institute.  NIH Publication No. 96-3291, Revised November 1996.

For further information, please contact:


Profile Therapeutics
John Lisle, Chief Executive Officer                  Tel: 0870 770 2000
Simon McGuire, Sales & Marketing Director

Buchanan Communications                              Tel: 020 7466 5000
Tim Anderson
James Strong


Notes to Editors:

Profile Therapeutics plc develops and commercialises specialist inhaled
therapies to improve the treatment of respiratory patients. Profile's core
patient groups are the young, the elderly and individuals with severe
respiratory impairment.  The diseases targeted by Profile include: cystic
fibrosis, pulmonary hypertension, asthma, emphysema, chronic bronchitis, sleep
disorders and Chronic Obstructive Pulmonary Disease ("COPD").

Profile has developed proprietary innovative delivery systems using its "
intelligent inhaler" technology known as Adaptive Aerosol Delivery or AAD.
These systems automatically respond to individual patients' breathing patterns
to deliver a precise dose and have been shown under long-term clinical trials to
significantly enhance patient compliance to therapy.

The agreement with CoTherix is the latest in Profile's continuing strategy to
realise the value of medicines through the AAD platform.  Profile's first drug
PromixinTM, an inhaled antibiotic for the treatment of patients with cystic
fibrosis, was launched in the UK in March 2003.  Schering's Ventavis is the
second medicine to be delivered using the Prodose.  Profile has also formed a
joint venture with Breath Ltd. to develop a range of respiratory medicines for
the US market with the Prodose HandHeld, which is currently in development for
launch in 2004.

CoTherix Inc. is a Belmont, CA US-based biopharmaceutical company.  It recently
raised $55m for the development of its inhaled Iloprost product for pulmonary
hypertension.


                      This information is provided by RNS
            The company news service from the London Stock Exchange
END

CNTUVUBROBRURAA